Terns PharmaceuticalsTERN
About: Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
Employees: 59
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
141% more call options, than puts
Call options by funds: $989K | Put options by funds: $410K
18% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 39
6.26% less ownership
Funds ownership: 101.4% [Q4 2024] → 95.13% (-6.26%) [Q1 2025]
13% less funds holding
Funds holding: 156 [Q4 2024] → 136 (-20) [Q1 2025]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 3 (-1) [Q1 2025]
43% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 42
52% less capital invested
Capital invested by funds: $477M [Q4 2024] → $229M (-$248M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
BMO Capital Etzer Darout | 376%upside $15 | Outperform Maintained | 13 May 2025 |
JMP Securities Silvan Tuerkcan | 535%upside $20 | Market Outperform Reiterated | 21 Apr 2025 |
Financial journalist opinion
Based on 4 articles about TERN published over the past 30 days









